- Home
- CDTX vs ZNTL Comparison
CDTX vs ZNTL Comparison
Compare CDTX & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CDTX | ZNTL |
|---|---|---|
| Founded | 2012 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 118.3M |
| IPO Year | 2015 | 2020 |
Fundamental Metrics
Financial Performance| Metric | CDTX | ZNTL |
|---|---|---|
| Price | $220.50 | $1.41 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 6 |
| Target Price | ★ $128.75 | $5.87 |
| AVG Volume (30 Days) | ★ 2.3M | 494.2K |
| Earning Date | 11-06-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $26,865,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $15.22 | $1.01 |
| 52 Week High | $221.20 | $3.53 |
Technical Indicators
Market Signals| Indicator | CDTX | ZNTL |
|---|---|---|
| Relative Strength Index (RSI) | 86.62 | 49.05 |
| Support Level | $219.60 | $1.34 |
| Resistance Level | $220.38 | $1.45 |
| Average True Range (ATR) | 0.74 | 0.06 |
| MACD | -3.92 | 0.01 |
| Stochastic Oscillator | 67.82 | 52.94 |
Price Performance
Historical ComparisonAbout CDTX Cidara Therapeutics Inc.
Cidara Therapeutics Inc is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. Its clinical-stage asset is CD388, a DFC intended for influenza prophylaxis. The Company's portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including DFCs from its proprietary Cloudbreak platform targeting oncologic, viral and autoimmune diseases.
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.